Some images has been designed using resources from Unsplash & Pixabay & Pexels & Freepik and some icons from Flaticon
跳到主要內容
:::

李國華 (Kuo-Hua Lee)

[Profile]

  • Education
    • MD, School of Medicine; Fu Jen Catholic University,
    • PhD, Institute of Clinical Medicine; National Yang Ming Chiao Tung University,
  • Career and Experience
    Current Positions:
    • - Now, Attending physician, Division of Nephrology, Taipei Veterans General Hospital,
    Experiences:
    • - , Chief resident, Division of Nephrology, Taipei Veterans General Hospital,
    • - , Chief resident, Department of Medicine, Taipei Veterans General Hospital,
    • - , Attending physician of IDS program, Department of Medicine , Taipei Veterans General Hospital,
  • Medical Expertise
    1. Nephrology
    2. Dialysis
  • License
    License of physician, Taiwan Board of Taiwan Society of Internal Medicine Board of Taiwan Society of Nephrology
  • Language Expertise
    Mandarin Taiwanese English

[Publications]

1.Artificial Intelligence for Risk Prediction of End-stage Renal Disease in Sepsis Survivors With Chronic Kidney Disease. Lee KH, Chu YC, Tsai MT, Tseng WC, Lin YP, Ou SM, Tarng DC*. Biomedicines. 2022 Feb 24;10(3):546

2.Iron Therapy in Chronic Kidney Disease: Days of Future Past. Lee KH, Ho Y, Tarng DC*. Int. J. Mol. Sci. 2021, 22(3), 1008

3.AN69 Filter Membranes with High Ultrafiltration Rates during Continuous Venovenous Hemofiltration Reduce Mortality in Patients with Sepsis-Induced Multiorgan Dysfunction Syndrome. Lee KH, Ou SM, Tsai MT, Tseng WC, Yang CY, Lin YP, Tarng DC*. Membranes (Basel). 2021 Oct 29;11(11):837

4.Antithrombotic Therapy for Chronic Kidney Disease Patients With Concomitant Atrial Fibrillation and Coronary Artery Disease.  Lee KH, Ou SM, Chu YC, Lin YP, Tsai MT, Tarng DC*. Front Cardiovasc Med. 2021 Oct 8;8:751359

5.The Anti-Inflammatory, Anti-Oxidative, and Anti-Apoptotic Benefits of Stem Cells in Acute Ischemic Kidney Injury. Lee KH, Tseng WC, Yang CY, Tarng DC*. Int. J. Mol. Sci. 2019, 20(14), 3529

回到最上